Concert Pharmaceuticals Stock Forecast, Price & News

+0.18 (+4.20 %)
(As of 06/15/2021 05:20 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume309,672 shs
Average Volume392,273 shs
Market Capitalization$143.82 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Concert Pharmaceuticals logo

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert Pharmaceuticals has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.53 out of 5 stars

Medical Sector

522nd out of 2,100 stocks

Pharmaceutical Preparations Industry

253rd out of 832 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions

Is Concert Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Concert Pharmaceuticals stock.
View analyst ratings for Concert Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Concert Pharmaceuticals?

Wall Street analysts have given Concert Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Concert Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Concert Pharmaceuticals' next earnings date?

Concert Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Concert Pharmaceuticals

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced its earnings results on Tuesday, May, 4th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.66) by $0.01. The biotechnology company earned $0.01 million during the quarter, compared to analysts' expectations of $1.50 million. Concert Pharmaceuticals had a negative trailing twelve-month return on equity of 59.51% and a negative net margin of 974.15%.
View Concert Pharmaceuticals' earnings history

How has Concert Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Concert Pharmaceuticals' stock was trading at $8.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CNCE shares have decreased by 46.8% and is now trading at $4.44.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CNCE?

4 analysts have issued 12 month target prices for Concert Pharmaceuticals' stock. Their forecasts range from $13.00 to $25.00. On average, they expect Concert Pharmaceuticals' stock price to reach $19.25 in the next twelve months. This suggests a possible upside of 333.6% from the stock's current price.
View analysts' price targets for Concert Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the following people:
  • Mr. Richard H. Aldrich M.B.A., Mba, Co-Founder & Chairman (Age 67, Pay $80k)
  • Dr. Roger D. Tung, Co-Founder, CEO, Pres & Exec. Director (Age 61, Pay $914.16k)
  • Ms. Nancy Stuart, Chief Operating Officer (Age 63)
  • Dr. James V. Cassella, Chief Devel. Officer (Age 66, Pay $691.36k)
  • Mr. Marc A. Becker, CFO & Principal Accounting Officer (Age 49)
  • Ms. Justine E. Koenigsberg, Sr. VP of Corp. Communications and Investor Relations
  • Mr. Jeffrey A. Munsie, Chief Legal Officer & Corp. Sec. (Age 44)
  • Dr. Ian Robert Silverman J.D., Ph.D., Sr. Legal Advisor (Age 68)

What is Roger Tung's approval rating as Concert Pharmaceuticals' CEO?

1 employees have rated Concert Pharmaceuticals CEO Roger Tung on Roger Tung has an approval rating of 100% among Concert Pharmaceuticals' employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Concert Pharmaceuticals' key competitors?

What other stocks do shareholders of Concert Pharmaceuticals own?

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Who are Concert Pharmaceuticals' major shareholders?

Concert Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.43%), BlackRock Inc. (7.23%), Ingalls & Snyder LLC (4.52%), Dimensional Fund Advisors LP (3.13%), Millennium Management LLC (3.13%) and Renaissance Technologies LLC (2.87%). Company insiders that own Concert Pharmaceuticals stock include Heek Christi Van, Jeffrey A Munsie, Nancy Stuart, Peter Barton Hutt, Roger D Tung and Thomas G Auchincloss.
View institutional ownership trends for Concert Pharmaceuticals

Which institutional investors are selling Concert Pharmaceuticals stock?

CNCE stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Goldman Sachs Group Inc., Northern Trust Corp, Man Group plc, Russell Investments Group Ltd., Public Employees Retirement System of Ohio, Nuveen Asset Management LLC, and The Manufacturers Life Insurance Company. Company insiders that have sold Concert Pharmaceuticals company stock in the last year include Jeffrey A Munsie, Nancy Stuart, and Roger D Tung.
View insider buying and selling activity for Concert Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Concert Pharmaceuticals stock?

CNCE stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Acadian Asset Management LLC, Renaissance Technologies LLC, Geode Capital Management LLC, Assenagon Asset Management S.A., BlackRock Inc., Millennium Management LLC, and Ingalls & Snyder LLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Heek Christi Van, and Thomas G Auchincloss.
View insider buying and selling activity for Concert Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $4.44.

How much money does Concert Pharmaceuticals make?

Concert Pharmaceuticals has a market capitalization of $142.83 million and generates $7.90 million in revenue each year. The biotechnology company earns $-74,770,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.

How many employees does Concert Pharmaceuticals have?

Concert Pharmaceuticals employs 71 workers across the globe.

What is Concert Pharmaceuticals' official website?

The official website for Concert Pharmaceuticals is

Where are Concert Pharmaceuticals' headquarters?

Concert Pharmaceuticals is headquartered at 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]

This page was last updated on 6/15/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.